95
Participants
Start Date
January 31, 2004
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
BL22 immunotoxin
BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
antibody-drug conjugate therapy
CD22 antibody, RFB4 on day 7
immunotoxin therapy
tested for immunogenicity to CAT-8015 before each cycle and at end of study.
monoclonal antibody therapy
administered intravenously over 30 minutes.
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda
Lead Sponsor
Collaborators (1)
Cambridge Antibody Technology
OTHER
MedImmune LLC
INDUSTRY